Walleye Capital LLC Increases Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)

Walleye Capital LLC increased its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 2,119.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 434,460 shares of the company’s stock after buying an additional 414,884 shares during the period. Walleye Capital LLC owned about 0.32% of Vir Biotechnology worth $3,189,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. XTX Topco Ltd purchased a new position in shares of Vir Biotechnology during the 4th quarter valued at approximately $177,000. Quinn Opportunity Partners LLC acquired a new stake in shares of Vir Biotechnology in the 4th quarter valued at about $484,000. Renaissance Technologies LLC lifted its position in shares of Vir Biotechnology by 4.7% during the fourth quarter. Renaissance Technologies LLC now owns 1,237,600 shares of the company’s stock worth $9,084,000 after purchasing an additional 55,300 shares during the last quarter. Invesco Ltd. grew its stake in Vir Biotechnology by 0.6% in the fourth quarter. Invesco Ltd. now owns 398,772 shares of the company’s stock worth $2,927,000 after purchasing an additional 2,574 shares in the last quarter. Finally, Polymer Capital Management US LLC bought a new stake in Vir Biotechnology in the fourth quarter valued at about $101,000. 65.32% of the stock is owned by hedge funds and other institutional investors.

Vir Biotechnology Stock Up 1.3 %

Shares of NASDAQ VIR opened at $5.50 on Friday. The firm’s 50-day simple moving average is $7.33 and its 200 day simple moving average is $8.12. The stock has a market cap of $754.29 million, a P/E ratio of -1.40 and a beta of 1.14. Vir Biotechnology, Inc. has a fifty-two week low of $4.95 and a fifty-two week high of $14.45.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.09. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The company had revenue of $12.37 million during the quarter, compared to analyst estimates of $8.14 million. On average, sell-side analysts anticipate that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Backer Marianne De sold 79,712 shares of the stock in a transaction on Thursday, April 3rd. The stock was sold at an average price of $5.95, for a total transaction of $474,286.40. Following the completion of the sale, the chief executive officer now owns 769,505 shares in the company, valued at approximately $4,578,554.75. This represents a 9.39 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director George A. Scangos sold 10,964 shares of Vir Biotechnology stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $9.81, for a total value of $107,556.84. Following the completion of the transaction, the director now owns 708,295 shares in the company, valued at $6,948,373.95. The trade was a 1.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 99,611 shares of company stock worth $663,525. 15.60% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Morgan Stanley upgraded Vir Biotechnology from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $10.00 to $20.00 in a report on Thursday, January 9th. JPMorgan Chase & Co. lifted their price target on shares of Vir Biotechnology from $10.00 to $14.00 and gave the company a “neutral” rating in a report on Thursday, January 9th. HC Wainwright reiterated a “buy” rating and set a $110.00 price objective on shares of Vir Biotechnology in a research note on Friday, February 28th. The Goldman Sachs Group lowered their target price on Vir Biotechnology from $28.00 to $21.00 and set a “buy” rating for the company in a report on Thursday. Finally, Barclays boosted their price objective on Vir Biotechnology from $26.00 to $31.00 and gave the company an “overweight” rating in a research report on Friday, February 28th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $33.57.

Vir Biotechnology Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).